These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7711671)

  • 21. Thalidomide back in good graces--seems to help GVHD patients.
    Oncology (Williston Park); 1988 Sep; 2(9):29. PubMed ID: 3275064
    [No Abstract]   [Full Text] [Related]  

  • 22. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis.
    Elhasid R; Arush MB; Zaidman I; Leiba R; Barak AB; Postovsky S; Haddad N; Katz T; Pollack S; Sami I; Gidoni O; Rubin D; Mandel H; Attias D; Reisner Y; Etzioni A; Rowe JM
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):329-38. PubMed ID: 17317586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature.
    Kanold J; Merlin E; Halle P; Paillard C; Marabelle A; Rapatel C; Evrard B; Berger C; Stephan JL; Galambrun C; Piguet C; D'Incan M; Bordigoni P; Deméocq F
    Transfusion; 2007 Dec; 47(12):2276-89. PubMed ID: 17764513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia.
    Mehta J; Powles R; Singhal S; Iveson T; Treleaven J; Catovsky D
    Bone Marrow Transplant; 1996 Mar; 17(3):371-5. PubMed ID: 8704689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avascular necrosis of the femoral head secondary to corticosteroid therapy for graft-versus-host disease after marrow transplantation: effective therapy with hip arthroplasty.
    Atkinson K; Cohen M; Biggs J
    Bone Marrow Transplant; 1987 Dec; 2(4):421-6. PubMed ID: 3332189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T; Kojima S; Kato K
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partially mismatched related donor bone marrow transplantation as salvage for patients with AML who failed autologous stem cell transplant.
    Godder KT; Mehta J; Chiang KY; Adams S; van Rhee F; Singhal S; Higgins-Smith K; O'Neal W; DeRienzo S; Henslee-Downey JP
    Bone Marrow Transplant; 2001 Dec; 28(11):1031-6. PubMed ID: 11781612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD.
    Bertz H; Afting M; Kreisel W; Duffner U; Greinwald R; Finke J
    Bone Marrow Transplant; 1999 Dec; 24(11):1185-9. PubMed ID: 10642806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Organ tolerance following cadaveric liver transplantation for chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Urban CH; Deutschmann A; Kerbl R; Lackner H; Schwinger W; Königsrainer A; Margreiter R
    Bone Marrow Transplant; 2002 Oct; 30(8):535-7. PubMed ID: 12379895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD.
    Levine JE; Wiley J; Kletzel M; Yanik G; Hutchinson RJ; Koehler M; Neudorf S
    Bone Marrow Transplant; 2000 Jan; 25(1):13-8. PubMed ID: 10654008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic graft-versus-host disease: a prospective cohort study.
    Arora M; Burns LJ; Davies SM; Macmillan ML; Defor TE; Miller WJ; Weisdorf DJ
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):38-45. PubMed ID: 12533740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.